Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:08:29.098Z.
Calculation as of: 2026-10-06T19:08:29.098Z.
Quote observation: 2026-10-06T19:05:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ddbbc57cb4d55ad36c9ea810397d6785d98e1ed361c578be0001995c9b2602d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Traws Pharma, Inc.
Market Cap
$7.94M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Traws Pharma, Inc. (TRAW) | $7.94M | N/A |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.91M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.76M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.74M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.15M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.71M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.22M | N/A |
| HeartSciences Inc. (HSCS)vs › | $8.25M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.32M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
